MenaQ7 Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos.

OSLO, NORWAY and METUCHEN, NJ (6 June 2017) – NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”.

Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the No. 1 pharmaceutical company for cardiology prescriptions. More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in Vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 Vitamin K2 as MK-7, specifically the cardiovascular benefits.

“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr. Hogne Vik, NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr. Francisco Fonseca.

According to Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are excited about Doiska MenaQ7® arrival in the pharmacies, expected by beginning of August this year. “We are confident the partnership between NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”

# # #

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and

international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

About Biolab Farmacêutica

Leader in the Brazilian market for medicines under medical prescription in the area of Cardiology, Biolab has a relevant role in the areas of Gynecology, Dermatology, Gastroenterology, Rheumatology, Orthopedics, Pediatrics, among others. Its focus is innovative medicines, which make up more than 50% of the company’s portfolio, made up of more than 100 products. Biolab has more than 2,000 employees and visits 250,000 doctors monthly in Brazil. For more information, visit http://www.biolabfarma.com.br/.

 

For more information, please contact:

Kate Quackenbush, Director of Communications

NattoPharma USA, Inc.

Phone: 609-643-0749

E-mail: kate.quackenbush@nattopharma.com